广州医药2024，Vol.55Issue(7)：747-751,5.DOI:10.3969/j.issn.1000-8535.2024.07.008
氟哌噻吨美利曲辛联合帕罗西汀对重度抑郁障碍患者躯体化症状、睡眠和认知功能的影响分析
Analysis of the effect of haloperitoxine melitrexine in combination with paroxetine on somatic symptoms,sleep and cognitive function in patients with major depressive disorder
摘要
Abstract
Objective To investigate the effect of haloperitoxine melitraxine combined with paroxetine on somatic symptoms,sleep and cognitive function in patients with major depressive disorder(MDD)and its clinical application effects.Methods A retrospective analysis was performed on the relevant data of 120 patients with MDD who received treatment in our hospital from August 2020 to February 2023,and divided into conventional group(treated with paroxetine,55 cases)and combined group(haloperitoxetex melitraxine combined with paroxetine,65 cases)according to their different treatment regimens.The treatment duration of the two groups was 4 weeks,and the Hamilton Rating Scale for Depression(HAMD-17)score,Somatized Symptom Self-rating Scale(SSS)score,Sleep Quality Score(PSQI)and Neuropsychological State Rating Scale(RBANS)scores were compared before treatment and at the 2nd and 4th week of treatment.After treatment,the patients were followed up for 1 month,and the total efficacy and adverse reactions of the two groups of patients after treatment were compared.Results After 2 and 4 weeks of treatment,the combined group showed significantly higher RBANS scores compared to the control group(P＜0.05),while PSQI scores,SSS scores and HAMD-17 scores were significantly lower in the combined group compared to the control group(P＜0.05).One month after treatment,follow-up data showed that there was no statistically significant difference in the overall incidence of adverse reactions between the two groups(P＞0.05).Additionally,the total effective rate was significantly higher in the combined group compared to the control group(P＜0.05).Conclusions Haloperitoxine melitrexine combined with paroxetine has a definite clinical effect in patients with MDD,and can also help patients reduce somatization symptoms,improve patients'sleep quality,and improve patients'cognitive function.关键词
氟哌噻吨美利曲辛/帕罗西汀/联合用药/重度抑郁症/躯体化症状/睡眠/认知功能Key words
haloperithioxine melitraxine/paroxetine/combination medications/major depressive disorder/somatization symptoms/sleep/cognitive function引用本文复制引用
刘晓燕,谭美玉,郭洋达,陈腊梅..氟哌噻吨美利曲辛联合帕罗西汀对重度抑郁障碍患者躯体化症状、睡眠和认知功能的影响分析[J].广州医药,2024,55(7):747-751,5.基金项目
江西省卫生健康委科技计划(20204108) （20204108）
